The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- Ebola vaccine study results published: 100% protection in Ebola challenged rhesus macaques on January 17, 2018 at 4:19 am
Yesterday, GeoVax Labs, Inc. announced the publication of its manuscript entitled “A Single-Dose of Modified Vaccinia Ankara Expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge” in the peer-reviewed open ... […]
- Vaccine Industry Retools Itself for Speed on January 15, 2018 at 11:18 am
The vaccine industry needs to consolidate diverse technological advances if it is to truly hit its stride and respond to fast-emerging dangers such as Ebola and Zika. Fortunately, speed-enhancing technologies are available, and they may be implemented up ... […]
- UCLA research team finds that Ebola survivors retain immunity on January 11, 2018 at 11:45 pm
The presence of reactive antibodies, a component of the immune system important for long-term resistance to diseases, suggests that Ebola vaccines may prevent future outbreaks, according to the study. “There are now 10 to 15 thousand Ebola survivors in ... […]
- 2018 Human Vaccines Market Trends | Middle East and Africa Industry Demand | Detail Overview and Forecasts Till 2022 on January 10, 2018 at 7:30 am
... trends include strong research pipeline under which number of novel vaccines are being developed such as rubella vaccine, ebola vaccine etc. DNA recombinant technology is also a common technology used in the development of novel acting vaccines. […]
- W.H.O. Approves a Safe, Inexpensive Typhoid Vaccine on January 8, 2018 at 6:51 pm
Bharat, which makes vaccines against nine other diseases, including one approved by the W.H.O. for polio, is developing immunizations against Ebola, chikungunya, Zika and non-typhoid strains of Salmonella. Its research is supported by the Bill and Melinda ... […]
- 9 dangerous diseases that could be prevented by vaccines within the next decade, from HIV to cancer on January 1, 2018 at 4:03 pm
... three countries are set to take part in a pilot program for a malaria vaccine starting in 2018, the World Health Organization said in a news release. An early Ebola vaccine has been shown to give solid protection against the disease. In a large ... […]
- Ebola vaccine approved for Congo amid outbreak in remote region on May 31, 2017 at 3:27 am
Officials in the Democratic Republic of the Congo have approved the use of an experimental Ebola vaccine in the hopes of stemming the spread of a recent outbreak of the deadly virus in the African nation. While DRC officials approved the use of rVSV-ZEBOV ... […]
- Ebola vaccine gives 100% protection, study finds on December 22, 2016 at 7:53 pm
(CNN)An experimental vaccine against the Ebola virus was found to be 100% effective, according to a study published in The Lancet on Thursday. The results offer hope of better protection against the disease that ravaged West Africa in 2014, killing more ... […]
- Ebola vaccine tests on monkeys show promise on September 8, 2014 at 4:24 am
Experimental Ebola vaccine protects healthy monkeys from the virus, tests show Tests of an experimental Ebola vaccine have shown positive results, protecting healthy monkeys from contracting the virus, the National Institutes of Health announced Sunday, as ... […]
- Human Trial for Ebola Vaccine to Begin This Week on September 1, 2014 at 5:59 am
Schaffner told ABC News in July. “It’s a little more complicated than that.” GlaxoSmithKline became involved in the Ebola vaccine because it bought Swiss vaccine company Okairos AG in 2013. Okairos, originally a Merck spinoff, had been working on the ... […]
via Google News and Bing News